Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 1/20 | 0.38 |
| ▸ | JAK1 | P23458 | 15/20 | 0.37 |
| ▸ | JAK2 | O60674 | 12/20 | 0.37 |
| ▸ | RAB9A | P51151 | 2/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27199464 | 0.81 | PARP1 (0.34) | JAK2RAB9ANPC1 | |
| SCHEMBL25670291 | 0.80 | CNR2 (0.39) | CNR2RXFP1 | |
| SCHEMBL25670769 | 0.75 | CNR2 (0.42) | CNR2RXFP1 | |
| SCHEMBL25750429 | 0.75 | ELANE (0.38) | CNR2 | |
| SCHEMBL20905336 | 0.73 | P2RX7 (0.42) | CNR2RXFP1 | |
| SCHEMBL5777669 | 0.73 | JAK1 (0.39) | CNR2JAK1RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL17390354 | 0.73 | RXFP1 (0.40) | CNR2JAK1RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL25752494 | 0.73 | ATR (0.41) | CNR2 | |
| SCHEMBL25752652 | 0.73 | CNR2 (0.39) | CNR2RAB9ANPC1RXFP1 | |
| SCHEMBL25752562 | 0.73 | OPRM1 (0.36) | CNR2JAK1RXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250115597-A1 | TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF | LYNK PHARMACEUTICALS CO LTD (CN) | 2025-04-10 | — | — | US | disclosed |
| CN-118401516-A | TYK2 inhibitors, compositions and methods thereof | 凌科药业(杭州)有限公司 | 2024-07-26 | — | — | CN | disclosed |
| US-20240124448-A1 | TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF | LYNK PHARMACEUTICALS CO. LTD. (CN) | 2024-04-18 | — | — | US | disclosed |
| WO-2023109954-A1 | TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF | LYNK PHARMACEUTICALS CO. LTD. (CN) | 2023-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240124448-A1 | TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF | TYK2, JAK2, JAK1 | CNR2 3169/4885JAK1 3/4885JAK2 2/4885 |
| US-20250115597-A1 | TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF | TYK2, JAK2, JAK1 | CNR2 3169/4885JAK1 3/4885JAK2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.